期刊文献+

新辅助化疗联合肿瘤细胞减灭术治疗晚期上皮性卵巢癌临床观察 被引量:15

下载PDF
导出
摘要 目的观察新辅助化疗(NACT)联合肿瘤细胞减灭术治疗晚期卵巢癌的临床疗效。方法将101例晚期卵巢癌患者分为两组,观察组术前予铂类为基础的腹腔内化疗1~2个疗程,2~3周后行肿瘤细胞减灭术;对照组首先行肿瘤细胞减灭术,再予化疗。观察两组失血量、腹水量、手术时间、术后住院时间、理想减瘤及非理想减瘤例数、并发症、临床疗效、复发、死亡、生存率。结果与对照组比较,观察组失血量少,腹水量少,手术时间短,理想减瘤例数多,非理想减瘤例数少,并发症少,总有效率高(P均<0.05);余指标比较均无统计学差异。结论 NACT联合肿瘤细胞减灭术治疗晚期卵巢癌疗效较好,值得临床借鉴。
出处 《山东医药》 CAS 2013年第19期78-79,共2页 Shandong Medical Journal
  • 相关文献

参考文献8

二级参考文献11

  • 1[1]Topalian SL,Muul LM,Solomon D,et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods, 1987,102:127~ 134. 被引量:1
  • 2[2]Lawton FG. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced unresected ovarian cancer. Obstet Gynecol, 1989,73: 61. 被引量:1
  • 3[3]Wils J. Primary and delayed debulking surgery and chemotherapy consisting of cisplatin doxorubicin and cyclophosphamide in stage Ⅲ - Ⅳ epithelial ovarian carcinoma. J Clin Oncol, 1986,4 : 1068. 被引量:1
  • 4[4]Hoskins WJ. The influence of cytoreductive surgery on progression free interval and survival in epithelial ovarian cancer. Baillieres Cilnical Gynecol, 1989,3: 59. 被引量:1
  • 5[5]Boente-MP,Chi-DS,Hoskins-WJ. The role of surgery in the management of ovarian cancer ; primary and interval cytoreductive surgery. Semin-Oncol, 1998,25 (3): 326~34. 被引量:1
  • 6[6]Berek - JS, Trope - C, Vergote - I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann- Oncol, 1999,10 Suppl 1: 3 ~ 被引量:1
  • 7[7]7.Resnik-E;Taxy-JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol,1996,62(1) :123~127. 被引量:1
  • 8[8]Hacker NF. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol,1983,61:413. 被引量:1
  • 9[9]Platsoucas CD. Autologous tumor- specific T cell in malignant melanoma. Cancer Metastasis Rev, 1991,10:151~ 176. 被引量:1
  • 10[10]Markman M, Reichman B, Hares T, et al. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer, 1993,71:1565~1570. 被引量:1

共引文献55

同被引文献103

  • 1李昱川.术前新辅助化疗治疗晚期卵巢癌的疗效分析[J].实用癌症杂志,2014,29(2):220-221. 被引量:14
  • 2董晖.新辅助化疗或手术治疗ⅢC或Ⅳ期卵巢癌患者[J].中国老年学杂志,2015,35(1):230-231. 被引量:8
  • 3蔡晶,陈艳霞,王泽华,等.首次手术与间隔性肿瘤减灭术在晚期上皮性卵巢癌治疗价值的比较[C].中华医学会第十次全国妇产科学术会议论文集,2012 :81. 被引量:1
  • 4Revaux A, Rouzier R, Ballester M , et al. Comparison of morbidityand survival between primary and interval cytoreductive surgery inpatients after modified posterior pelvic exenteration for advanced o-varian cancer[ J]. Int J Gynecol Cancer,2012 ,22 (8) :1349 ~ 1354. 被引量:1
  • 5Lakhman Y, Akin O, Sohn MJ, et al. Early postoperative CT as aprognostic biomarker in patients with advanced ovarian,tubal,andprimary peritoneal cancer deemed optimally debulked at primary cy-toreductive surgery[J]. AJH ,2012 ,198(6) :1453 - 1459. 被引量:1
  • 6杨雯,宋磊,李立安,等.CA125及细胞减灭术在晚期上皮性卵巢癌新辅助化疗中的价值[C].中华医学会第十次全国妇产科学术会议论文集,2012 :200 - 201. 被引量:1
  • 7曹泽毅.中华妇产科学(下册)[M].第2版,北京:人民卫生出版社,2005:25-37. 被引量:1
  • 8KRASNER C, DUSKA L. Management of women with newly di- agnosed ovarian cancer[J]. Semin Oncol, 2009, 36(2): 91-105. 被引量:1
  • 9GLASGOW MA, YU H, RUTHERFORD TJ, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovrain cancer (FIGO Stage I and IV)[J]. J Surg Oncol, 2013, 107(2): 195-200. 被引量:1
  • 10VAN DER ZEE J. Heating the patient: a promising approach[J]. Ann Oncol, 2002, 13(8): 1173-1184. 被引量:1

引证文献15

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部